Richard Levine/Alamy MILWAUKEE -- Long before it was known for fine cheddar cheese or the Green Bay Packers, Wisconsin was famous for beer, especially the national brands brewed in Milwaukee: Schlitz, Blatz and Pabst Blue Ribbon. The brewing tradition started by Milwaukee's German immigrants in the 1800s endured for more than a century, until industry consolidation in the 1980s and '90s began sending familiar brands to other companies and cities. Now a small group of Milwaukee residents wants to revive part of that proud history by buying Pabst Brewing Co. from a California executive in hopes of returning the brand to its birthplace, possibly as a city-owned brewery. The effort appears to be a distant long shot, requiring hundreds of millions of dollars to acquire the 170-year-old beer best known as PBR. But Milwaukee officials like the idea enough to talk about it, and at least one industry analyst says the plan isn't beyond the realm of possibility. "When I think about Pabst being anywhere else but Milwaukee, it just doesn't make sense," said Susie Seidelman, an organizer of the "Bring Pabst Blue Ribbon Home" effort. "Milwaukee made this beer what it is. ... It's right on the can." The beer, with its pale gold color and light, fizzy taste, has become especially popular over the last decade among urban hipsters, in part because it's one of the cheapest on the market. The company that started in Milwaukee in 1844 is now headquartered in Los Angeles after being bought by food industry executive C. Dean Metropoulos in 2010 for a reported $250 million. Reports surfaced last month suggesting that Pabst might be looking for buyers. Organizers of the group want Metropoulos to give them first rights of sale so they can begin raising money toward any asking price. Pabst representatives wouldn't comment on any potential sale or the efforts to bring the brand back to Milwaukee, saying only that they "are considering financial alternatives" that will help Pabst "aggressively pursue its next phase of growth through strategic acquisitions."
Hot Oil Stocks For 2015: Waste Management Inc.(WM)
Waste Management, Inc., through its subsidiaries, provides waste management services to residential, commercial, industrial, and municipal customers in North America. It offers collection, transfer, recycling, and disposal services. The company also owns, develops, and operates waste-to-energy and landfill gas-to-energy facilities in the United States. Its collection services involves in picking up and transporting waste and recyclable materials from where it was generated to a transfer station, material recovery facility, or disposal site; and recycling operations include collection and materials processing, plastics materials recycling, and commodities recycling. In addition, it provides recycling brokerage, which includes managing the marketing of recyclable materials for third parties; and electronic recycling services, such as collection, sorting, and disassembling of discarded computers, communications equipment, and other electronic equipment. Further, the company e ngages in renting and servicing portable restroom facilities to municipalities and commercial customers under the Port-o-Let name; and involves in landfill gas-to-energy operations comprising recovering and processing the methane gas produced naturally by landfills into a renewable energy source, as well as provides street and parking lot sweeping services. Additionally, it offers portable self-storage, fluorescent lamp recycling, and medical waste services for healthcare facilities, pharmacies, and individuals, as well as provides services on behalf of third parties to construct waste facilities. The company was formerly known as USA Waste Services, Inc. and changed its name to Waste Management, Inc. in 1998. Waste Management, Inc. was incorporated in 1987 and is based in Houston, Texas.
Advisors' Opinion:- [By Chris Hill]
Waste Management (NYSE: WM ) reported a slight decline in first-quarter profits but revenues increased. Shares of the trash giant hit their highest point since 1999. In this installment of Motley Fool Money, our analysts talk about the future of Waste Management.
- [By Jake L'Ecuyer]
Waste Management (NYSE: WM) was down, falling 3.50 percent to $42.14 after the company reported weaker-than-expected Q4 results.
Commodities
In commodity news, oil traded up 1.01 percent to $101.36, while gold traded up 1.38 percent to $1,318.10. - [By Louis Navellier]
Waste and environmental services company Waste Management (WM) announced fourth-quarter results and a hefty new stock buyback program. With a 3.3% dividend yield and a firm handhold on the nation’s garbage collection market, could one man’s trash be a treasure in your portfolio?
Top 10 Healthcare Equipment Stocks To Buy For 2014: Acorda Therapeutics Inc.(ACOR)
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS with walking disability under the Fampyra name internationally. Its lead research and development programs include three biologic therapeutic approaches for restoring neurologic and cardiac function, which comprise Neuregulin Program for developing Glial Growth Factor 2, a molecule in the Phase I clinical trial for the treatment of heart failure; Remyelina ting Antibodies Program for developing rHIgM22, an antibody in the preclinical stage for treating MS; and Chondroitinase Program, a research stage program focused on developing chontroitinase as a therapeutic to break down inhibitory factors in the scar tissue that develops as a result of an injury to the CNS. In addition, the company has in-licensed a clinical-stage program, AC105, to develop an acute treatment for neurological trauma. It has collaboration agreement with Biogen Idec International GmbH to develop and commercialize products containing aminopyridines to the treatment of MS. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Hawthorne, New York.
Advisors' Opinion:- [By RichardCox]
With any rally, some examples of over-extension can be found. One stock to sell on the short side can be seen in Acorda Therapeutics (ACOR), which to some will look cheap with its low P/E ratio of 9.6. Looking at the fundamentals, product stories some potential obstacles. Looking at the walk-test data in the company's central offering (Ampyra) have been largely uninspiring. Because of this, further Phase IIb trials will likely be required before we can see a move into Phase III. This will almost certainly stall the development process - by as much as 2 years. This story will continue to drag on projections and create downward revisions in both sales growth and earnings projections and sales growth. Upside potential for this stock remains limited, and short selling opportunities await on any rallies:
- [By James E. Brumley]
Investors who were hoping things would work out for epilepsy treatment company Cyberonics, Inc. (NASDAQ:CYBX) can cross CYBX off their list of epilepsy-oriented stocks to buy, as they did with Acorda Therapeutics Inc. (NASDAQ:ACOR) about a month ago. ACOR saw its epilepsy drug Plumiaz rejected by the FDA in early May, while CYBX announced this morning that the coming fiscal year's (beginning in April) revenue would be weaker than first expected as sales of its epileptic control implant device didn't look quite as promising as hoped.
- [By Sean Williams]
What: Shares of Acorda Therapeutics (NASDAQ: ACOR ) , a commercial-stage biopharmaceutical company with a focus on central nervous system disorders, jumped as much as 13% after the company reported positive phase 2 trial data for experimental drug Ampyra for the treatment of post-stroke deficits.
Top 10 Healthcare Equipment Stocks To Buy For 2014: Koninklijke DSM NV (RDSMY.PK)
Koninklijke DSM N.V. (DSM), incorporated on December 28, 1966, is engaged in creating products and services in Life Sciences and Materials Sciences. DSM�� products and services are used in a range of markets and applications. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. The activities of DSM are grouped into five clusters: Nutrition, Pharma, Performance Materials, Polymer Intermediates, and Base Chemicals and Materials. In May 2010, Orascom Construction Industries announced that the acquisition of the Company�� agro and melamine businesses has been finalized. DSM completed the disposal of DSM Energie Holding B.V. (DSM Energy) to TAQA Abu Dhabi National Energy Company PJSC on September 30, 2009. In September 2010, the Company acquired Microbia, Inc. from Ironwood Pharmaceuticals, Inc. In December 2010, the Company completed the sale of DSM Special Products B.V. to Emerald Performance Materials. In February 2011, the Company completed the acquisition of Martek Biosciences Corporation. In May 2011, the Company sold DSM Elastomers to Lanxess AG. In June 2012, the Company acquired Kensey Nash Corporation (Kensey Nash).
Nutrition
The Nutrition cluster comprises DSM Nutritional Products and DSM Food Specialties. The nutrition and food ingredients businesses serve the food, feed, cosmetic and pharmaceutical industries. DSM holds positions in the markets for ingredients for human and animal nutrition and health. DSM Nutritional Products is the supplier of vitamins, carotenoids, nutritional ingredients, ultra-violet (UV) filters and premixes for human and animal nutrition and health. DSM Nutritional Products is organized around two entities: Animal Nutrition and Health (ANH) and Human Nutrition and Health (HNH). DSM Food Specialties is a global manufacturer of food enzymes, cultures, yeast extracts and other specialty ingredients for the food and b! everage industries.
DSM Food Specialties comprises two business units and an Ingredients Development Unit. Enzymes & Dairy Ingredients supplies a range of food enzymes for applications such as dairy, baking, fruit processing, brewing and wine, starter cultures for cheese and yogurt, preservation solutions for cheese and meat, and tests for the detection of residues of antibiotics in milk. Savoury Ingredients is a major supplier of ingredients for flavorings and flavor enhancers (such as yeast extracts) used in products, such as soups, instant meals, sauces and savory snacks.
Pharma
The Pharma cluster comprises the business groups DSM Pharmaceutical Products (DPP) and DSM Anti-Infectives. DSM is an independent supplier to the pharmaceutical industry. DSM Pharmaceutical Products is a provider of custom contract manufacturing and development services to the pharmaceutical, biopharmaceutical and agrochemical industries.
DSM Pharmaceutical Products consists of three business units: DSM Pharma Chemicals (custom chemical manufacturing services for complex registered intermediates and active pharmaceutical ingredients (APIs), including DSM Exclusive Synthesis (custom manufacturing services for the crop protection industry), DSM Biologics (biopharmaceutical manufacturing technology and services) and DSM Pharmaceuticals, Inc. (finished-dose-form manufacturing services). DSM BioSolutions focuses on custom manufacturing services based on microbial fermentation. DSM Anti-Infectives holds global leadership positions in penicillin G, penicillin intermediates (6-APA and 7-ADCA), active pharmaceutical ingredients such as semi-synthetic penicillins and semi-synthetic cefalosporins (beta-lactams), and other active ingredients, such as nystatin.
Performance Materials
The Performance Materials cluster comprises the business groups DSM Engineering Plastics, DSM Dyneema and DSM Resins. The products are used in a variety of end-use markets: the au! tomotive ! industry, the aviation industry, the electrical and electronics industry, the sports and leisure industries, the paint and coatings industry and the construction industry.
DSM Engineering Plastics is a global player in polyamides, polyesters, polycarbonates and adhesive resins. These materials are used in components for the electrical and electronics, automotive, engineering and packaging industries. DSM produces Dyneema fiber and UD (unidirectional textile sheets) in Heerlen (Netherlands) and in Greenville (North Carolina, United States) through its gel-spinning process. DSM Resins consists of four business units: DSM NeoResins+, DSM Powder Coating Resins, DSM Desotech and DSM Composite Resins.
Polymer Intermediates
The Polymer Intermediates cluster consists of DSM Fiber Intermediates. DSM Fibre Intermediates produces caprolactam and acrylonitrile, which are raw materials for synthetic fibers and engineering plastics. Other products include ammonium sulfate (a fertilizer), diaminobutane, sodium cyanide and cyclohexanone. DSM�� caprolactam production capacity is more than 600,000 tons per annum.
Base Chemicals and Materials
The Base Chemicals and Materials cluster consists of DSM Agro, DSM Melamine, DSM Elastomers and a number of activities that have been carved out from other clusters. DSM Agro produces fertilizers and is active in Northwestern Europe. DSM Melamine is a producer of melamine, used in wood-based panels and laminates for furniture and flooring. DSM Elastomers manufactures synthetic rubbers (EPDM) for use in cars and other transportation vehicles, white goods, various industrial products and construction materials and as motor-oil additives.
DSM Agro is a producer of ammonia and high-nitrogen fertilizers for grasslands and agricultural crops; products and services for responsible fertilization. DSM Agro sells about 2.4 million tons of fertilizers per year. The Base Chemicals and Materials cluster also includes! several ! activities that have been carved out from other clusters. These include Citric Acid, DSM Special Products and the Maleic Anhydride and derivatives business.
Other activities
Other activities comprise various activities and businesses that do not belong to any of the five reporting clusters. It consists of both operating and service activities and also includes a number of costs that cannot be logically allocated to the clusters. Other activities includes the DSM Innovation Center, DSM Venturing and a number of other activities, such as Sitech Services, EdeA, DSM Insurances and part of the costs of corporate activities. Sitech Services provides technological consultancy, expertise in energy and auxiliary materials, the supply of utilities and human resources.
EdeA VoF owns, operates and maintains most of the production and distribution facilities for utilities (for example steam, power and water) at the Chemelot site in Sittard-Geleen (Netherlands). EdeA VoF is a joint venture with Essent, an energy production and distribution company. DSM�� stake is 50%. DSM retains a limited part of its Property Damage and Business Interruption and Product Liability risks via a captive insurance company. DSM has a share in a limited number of associates.
Advisors' Opinion:- [By Markus Aarnio]
BioAmber expects its advanced bio-based specialty chemicals to compete with petrochemical equivalents that are proven in the market and manufactured by established companies, such as Gadiv Petrochemical Industries, Kawasaki Kasei, DSM (RDSMY.PK) and numerous small Chinese producers including Anqing Hexing Chemical, and Anhui Sunsing Chemicals. In addition, BioAmber's products will compete against other companies in the bio-based specialty chemical industry, both early stage companies, such as Genomatica (for bio-based 1,4 BDO) and Myriant Corporation (for bio-succinic acid), and established companies, such as a collaborative venture between DSM and Roquette Frères S.A. and a collaborative venture between BASF (BASFY.PK) and Purac (both for bio-succinic acid).
Top 10 Healthcare Equipment Stocks To Buy For 2014: Compugen Ltd.(CGEN)
Compugen Ltd. operates as a drug and diagnostic discovery company based on computer-based discovery capabilities to predict and select novel product candidates. Through in silico prediction and selection, the resulting novel molecules are synthesized and validated utilizing traditional in vitro and in vivo experimental procedures. The company provides these validated product candidates to pharmaceutical, biotech, and diagnostic companies under licensing and other commercialization arrangements. Its research and discovery efforts are focused primarily on therapeutic proteins and peptides, and monoclonal antibodies, and primarily in the fields of immunology and oncology. Its therapeutic peptide and protein related platforms include Protein Family Members Discovery Platform, Protein-Protein Interaction Blockers, GPCR Therapeutic Peptide Ligands, Disease-Associated Conformation Blockers, Intracellular Drug Delivery, Viral Peptides, and Splice Variant based Therapeutic Proteins . The company?s monoclonal antibody related platforms comprise Monoclonal Antibody Targets. Its other therapeutic and diagnostic platforms consist of Nucleic-Acid Disease Markers, Protein Disease Markers, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, and New Indications. Its therapeutic peptide and protein product candidates comprise CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists; CGEN-25007, an antagonist of the gp96 protein; and CGEN-25009, a peptide of the LGR7 receptor. The company also offers monoclonal antibody target product candidates, including CGEN-671, a drug for multiple epithelial tumors; CGEN-928, a drug for multiple myeloma; and CGEN-15001T, a novel B7/CD28 family member. Compugen Ltd. was founded in 1993 and is based in Te l Aviv, Israel.
Advisors' Opinion:- [By Sean Williams]
On Monday, small-cap biotechnology company Compugen (NASDAQ: CGEN ) gave investors something to cheer about when it announced a collaboration and licensing agreement with Bayer for two of its antibody-based immunotherapies. The deal could be worth as much as $540 million for Compugen and gives the company $10 million upfront, as well as the potential for $30 million more in milestone payments during preclinical trials. The two companies will co-develop these drugs, with Bayer getting worldwide rights upon commercialization (though Compugen would still receive a mid- to high-single-digit royalty). This is great news for Compugen, as it solves the problem of seeking out a partner later, helps reduce its clinical testing costs, and staves off the need to dilute shareholders with a secondary offering to raise cash. Shares added 44% this week.
- [By Lisa Levin]
Compugen (NASDAQ: CGEN) climbed 3.54% to $11.86 after Jefferies initiated coverage on the stock with a Buy rating and a $17.00 price target.
Posted-In: market moversNews Intraday Update Markets Movers
Top 10 Healthcare Equipment Stocks To Buy For 2014: Glatfelter (GLT)
P. H. Glatfelter Company manufactures and sells specialty papers and fiber-based engineered materials in the United States and internationally. It offers carbonless and forms papers for credit card receipts, multi-part forms, security papers, and other end-user applications; book publishing papers for the production of hardbound books and other book publishing needs; envelope and converting papers for the direct mail market, shopping bags, and other converting applications; and engineered products for digital imaging, transfer, casting, release, postal, playing card, and other niche specialty applications. The company also provides food and beverage paper used for tea bags and single serve coffee products; metallized products used in the labeling of beer bottles, innerliners, gift wrap, self-adhesive labels, and other consumer products applications; and composite laminates papers used in production of decorative laminates, furniture, and flooring applications, as well as a line of paper products used in batteries, medical masks, and other engineered applications. In addition, it offers airlaid non-woven fabric-like materials used in feminine hygiene products, adult incontinence products, cleaning pads and wipes, food pads, napkins and tablecloths, and baby wipes. The company markets its products directly, as well as through wholesale paper merchants, brokers, and agents. P. H. Glatfelter Company was founded in 1864 and is headquartered in York, Pennsylvania.
Advisors' Opinion:- [By CRWE]
Glatfelter (NYSE:GLT) reported that the previously announced presentation by Dante C. Parrini, Chairman and Chief Executive Officer, at the Deutsche Bank Global Industrials and Basic Materials Conference on Wednesday, June 13, 2012 will be available via a live web cast.
- [By Marc Bastow]
Specialty papers and and fiber-based materials manufacturer P.H. Glatfelter (GLT) raised its quarterly dividend 10% to 11 cents per share, payable May 1 to shareholders of record as of April 3.
GLT Dividend Yield: 1.44%
Top 10 Healthcare Equipment Stocks To Buy For 2014: Time Warner Inc.(TWX)
Time Warner Inc. operates as a media and entertainment company in the United States and internationally. It operates in three segments: Networks, Filmed Entertainment, and Publishing. The Networks segment provides domestic and international networks, premium pay and basic tier television programming services, and digital media properties, which primarily consist of brand-aligned Websites. Its premium pay television services consist of the multi-channel HBO and Cinemax premium pay television services. This segment provides programming to cable system operators, satellite service distributors, telephone companies, and other distributors; sells advertising; and licenses original programming to domestic and international television networks. The Filmed Entertainment segment produces and distributes feature films, television and other programming, and videogames; distributes home video products; and licenses rights to its feature films, television programming, and characters. T he Publishing segment publishes magazines and books; and operates various Websites, as well as engages in marketing services and direct-marketing businesses. This segment publishes magazines on style and entertainment, lifestyle, news, and sports. The company?s brands include TNT, TBS, CNN, HBO, Cinemax, Warner Bros., New Line Cinema, People, Sports Illustrated, and Time. Time Warner Inc. was founded in 1985 and is headquartered in New York, New York.
Advisors' Opinion:- [By Tim Beyers]
Touchstone/Getty ImagesBen Affleck in a scene from the 1998 film "Armageddon." Only a handful of actors have been given the privilege of playing Batman. Last week, Ben Affleck joined a list that includes the likes of Adam West, Christian Bale and Kevin Conroy, who has voiced the character in animated features since 1992. He'll join Henry Cavill, who plays Superman, in an epic that pits the two iconic superheroes against each other. Time Warner (TWX) plans to release the film in July 2015. Many fans were outraged by the choice. "Christian Bale IS 'THE' BATMAN and I refuse to watch this movie even after it comes out on video," wrote one commenter to an article I published at Fool.com last week. Another organized a petition asking Warner to reconsider its choice. More than 85,000 have signed as of this writing. Tale of the Tape Are fans overreacting, or is Warner taking a huge chance by asking Affleck to play one of its most valuable superhero brands? I'd argue the former after looking at the data. Pound for pound, Affleck's credentials are about as good as Bale's: Metric Ben Affleck Christian Bale Films made 33 31 Lifetime gross (U.S.) $1.67 billion $1.91 billion Average per film $50.7 million $61.6 million Top-grossing film "Armageddon" ($537.7 million worldwide) "The Dark Knight Rises" ($1.08 billion worldwide) Lowest-grossing film "Glory Daze" ($15,134 worldwide) "All the Little Animals" ($26,558 worldwide) Academy Awards 2 1 Age / Height / Weight 41 / 6'2" / 200 lbs. 39 / 6' / 180 lbs. Comic book films "Daredevil" "Batman Begins" "The Dark Knight" "The Dark Knight Rises" Best-delivered line in a comic book film "Hey, that light? At the end of the tunnel? Guess what? That's not heaven ... That's the C train!"-- from "Daredevil" "You'll hunt me. You'll condemn me. Set the dogs on me. Because that's what needs to happen. Because sometimes the truth isn't good enough. Sometimes people deserve more. Sometimes people deserve to have their f
Top 10 Healthcare Equipment Stocks To Buy For 2014: Rofin-Sinar Technologies Inc.(RSTI)
Rofin-Sinar Technologies Inc., together with its subsidiaries, engages in the design, development, engineering, manufacturing, and marketing of laser-based products worldwide. The company offers laser macro products to machine tool and automotive markets for cutting and welding of metals. It also provides laser marking products to semiconductor and electronics markets for the marking of integrated circuits, wafers, solar cells, electronic components, and smart cards, as well as to automotive markets for the marking of labels and car components. In addition, the company offers laser micro products for fine welding, fine cutting, micro structuring, and drilling applications in medical devices, semiconductor and electronics, photovoltaic, dental, and jewelry markets; and for perforating and scribing of paper and foils in packaging and paper industries. Further, it provides components to laser industry. The company sells its products in approximately 65 countries to original e quipment manufacturers, systems integrators, and industrial end-users. Rofin-Sinar Technologies Inc. was founded in 1975 and is based in Plymouth, Michigan.
Advisors' Opinion:- [By Brian Stoffel]
Rofin-Sinar (NASDAQ: RSTI ) , Coherent (NASDAQ: COHR ) , Newport (NASDAQ: NEWP ) , and JDS Uniphase (NASDAQ: JDSU ) all offer fiber-optic lasers as well.
- [By Brian Stoffel]
For decades, the standard technology in the laser industry has been the carbon-based laser. In reality, these lasers are still commonly used, and sold in bulk by the likes of Rofin-Sinar (NASDAQ: RSTI ) and Coherent (NASDAQ: COHR ) . They are used largely for precision cutting of large pieces of metal.
No comments:
Post a Comment